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***Dear Editor,***

Acenocoumarol, is a racemic mixture of the optical R (+) and S (-) enantiomers. R (+) enantiomer is several times more potent than the S (-) enantiomer (Godbillon et al., 1981\[[@R1]\]). Acenocoumarol is rapidly absorbed following oral absorption with approximately 60 % of the dose available systemically (Trailokya, 2015\[[@R13]\]). After a single dose of 10 mg, the peak plasma concentrations (C~max~) of acenocoumarol are reached within 1-3 h and the area under the plasma concentration-time curve (AUC) values are proportional to the dose in the dosage range of 8 to 16 mg (Sasso et al., 2012\[[@R8]\]). The protein binding of acenocoumarol is 98 % (Trailokya et al., 2016\[[@R14]\]). Acenocoumarol is mainly metabolized by CYP2C9 (Trailokya, 2015\[[@R13]\]); 6- and 7-hydroxylation of both enantiomers of acenocoumarol are the major metabolites (Thijssen et al., 2000\[[@R11]\]). The elimination half-life of acenocoumarol is 8 to 11 h (Sánchez et al., 2013\[[@R7]\]). Approximately, 29 % of acenocoumarol excrete in feces and 60 % in urine. The starting dose of acenocoumarol usually ranged from 2 to 4 mg. Based on the prothrombin time, subsequent loading doses may be recommended (Trailokya, 2015\[[@R13]\]).

Acenocoumarol is reported to exhibit a dose-proportional pharmacokinetics for the 8 to 16 mg doses (Trailokya, 2015\[[@R13]\]). However, no information is available for the dose-proportionality of lower doses of acenocoumarol (i.e. 1 to 4 mg doses). We aimed to evaluate the dose-proportionality of acenocoumarol by performing a literature search and plotting a linear curve for AUC vs. dose from the available information.

Literature related to pharmacokinetics of acenocoumarol was searched in PubMed. A total of 115 from 1618 articles were identified related to acenocoumarol\'s pharmacokinetics. From, 115 articles, 9 articles were identified as potentially relevant, as these articles reported the AUC values at different time points such as 24, 48, 72 h and at infinite time. These articles were finally considered for the evaluation of linearity of acenocoumarol pharmacokinetics. Various studies have reported the AUC~0-48~ and AUC~0-∞~ values of acenocoumarol for 1, 4, 10 and 12 mg dose (Table 1[(Tab. 1)](#T1){ref-type="fig"}; References in Table 1: Huang et al., 2008\[[@R2]\]; Masche et al., 1999\[[@R3]\]; Popovic et al., 1994\[[@R4]\]; Rolan et al., 2003\[[@R6]\]; Sasso et al., 2012\[[@R8]\]; Sunkara et al., 2004\[[@R9]\]; Thijssen and Baars, 1983\[[@R10]\]; Thijssen and Hamulyàk, 1989\[[@R12]\]). No other information on AUC~0-48~ and AUC~0-∞~ were available with the 2, 8 and 16 mg dose. The pharmacokinetics data across these studies were used to generate a dose-proportionality curve (acenocoumarol dose vs. AUC~0-48~ or acenocoumarol dose vs. AUC~0-∞~). The dose-proportionality curves between AUC and acenocoumarol doses (AUC~0-48~vs. dose, and AUC~0-∞~ vs. dose) are presented in Figure 1[(Fig. 1)](#F1){ref-type="fig"}.

An R^2^ of 1 indicates that the regression predictions perfectly fit the data. Therefore, from the value of R^2^ (0.9988 for AUC~0-48~vs. dose, and 0.9874 for AUC~0-∞~vs. dose), it is clear that acenocoumarol exhibits a dose-proportional pharmacokinetics.
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